文献速递胸部肿瘤

色瑞替尼对比化疗在既往接受过化疗和克唑替尼的ALK重排非小细胞肺癌患者中的疗效(ASCEND-5):一项随机、对照、开放标签、3期试验

Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2017-06-09

ASCEND-5研究在20个国家99个中心纳入231例既往接受过化疗和克唑替尼后进展的ALK重排IIIB/IV期非小细胞肺癌患者,1:1随机接受色瑞替尼750 mg每日一次口服或化疗(培美曲塞500 mg/m2或度他西他赛75 mg/m2,每21天)。色瑞替尼组中位无进展生存期显著优于化疗组(5.4个月 vs 1.6个月;HR 0.49,95%CI 0.36-0.67;p<0.0001)。

要点

  • 色瑞替尼较化疗显著改善既往克唑替尼和化疗失败后的ALK重排NSCLC患者的无进展生存期(HR 0.49)。
  • 色瑞替尼组3-4级丙氨酸氨基转移酶升高24例(21%)vs 化疗组2例(2%)。
  • 色瑞替尼组治疗期间死亡15例(13%)vs 化疗组5例(4%),均经研究者评估与治疗无关。

核心结论

  • 色瑞替尼在既往克唑替尼和铂类化疗失败后的ALK重排非小细胞肺癌患者中较化疗显著改善无进展生存期。

研究设计与样本

  • 随机、对照、开放标签、3期试验,在20个国家99个中心纳入231例年龄≥18岁、ALK重排IIIB或IV期非小细胞肺癌患者。
  • 患者既往接受过1-2线化疗(包括铂类双药)和克唑替尼后进展,WHO体能状态0-2,预期寿命≥12周。
  • 按1:1随机分配至色瑞替尼750 mg每日一次空腹口服(21天为一周期)或化疗(培美曲塞500 mg/m2或度他西他赛75 mg/m2,每21天,由研究者选择)。
  • 按WHO体能状态(0 vs 1-2)和有无脑转移分层,采用区组随机(区组大小4)。
  • 主要终点为盲法独立审查委员会按RECIST 1.1评估的意向治疗人群无进展生存期,前18个月每6周评估一次,之后每9周评估一次。

主要发现

  • 2013年6月28日至2015年11月2日随机分配231例患者:色瑞替尼组115例(50%),化疗组116例(50%);化疗组中培美曲塞40例(34%)、度他西他赛73例(63%),3例(3%)在治疗前退出。
  • 中位随访16.5个月(IQR 11.5-21.4)。
  • 色瑞替尼组中位无进展生存期5.4个月(95%CI 4.1-6.9)vs 化疗组1.6个月(95%CI 1.4-2.8);HR 0.49(95%CI 0.36-0.67);p<0.0001。
  • 严重不良事件:色瑞替尼组49/115例(43%)vs 化疗组36/113例(32%);治疗相关严重不良事件:色瑞替尼组13例(11%)vs 化疗组12例(11%)。
  • 色瑞替尼组最常见的3-4级不良事件为丙氨酸氨基转移酶升高24/115例(21%)vs 化疗组2/113例(2%)、γ谷氨酰转移酶升高24例(21%)vs 1例(1%)、天冬氨酸氨基转移酶升高16例(14%)vs 1例(1%)。

关键数值与推荐

  • 色瑞替尼组中位无进展生存期5.4个月(95%CI 4.1-6.9)vs 化疗组1.6个月(95%CI 1.4-2.8);HR 0.49(95%CI 0.36-0.67);p<0.0001。
  • 色瑞替尼组3-4级丙氨酸氨基转移酶升高24/115例(21%)vs 化疗组2/113例(2%)。
  • 色瑞替尼组3-4级γ谷氨酰转移酶升高24/115例(21%)vs 化疗组1/113例(1%)。
  • 色瑞替尼组3-4级天冬氨酸氨基转移酶升高16/115例(14%)vs 化疗组1/113例(1%)。

临床怎么用

  • 作者认为,这些发现表明患者在克唑替尼治疗失败后可从更强效的ALK抑制剂获得显著临床获益,并确立色瑞替尼在该人群中为较化疗更有效的治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ceritinib is a next-generation anaplastic lymphoma kinase (ALK) inhibitor, which has shown robust anti-tumour efficacy, along with intracranial activity, in patients with ALK-rearranged non-small-cell lung cancer. In phase 1 and 2 studies, ceritinib has been shown to be highly active in both ALK inhibitor-naive and ALK inhibitor-pretreated patients who had progressed after chemotherapy (mostly multiple lines). In this study, we compared the efficacy and safety of ceritinib versus single-agent chemotherapy in patients with advanced ALK-rearranged non-small-cell lung cancer who had previously progressed following crizotinib and platinum-based doublet chemotherapy. METHODS: In this randomised, controlled, open-label, phase 3 trial, we recruited patients aged at least 18 years with ALK-rearranged stage IIIB or IV non-small-cell lung cancer (with at least one measurable lesion) who had received previous chemotherapy (one or two lines, including a platinum doublet) and crizotinib and had subsequent disease progression, from 99 centres across 20 countries. Other inclusion criteria were a WHO performance status of 0-2, adequate organ function and laboratory test results, a life expectancy of at least 12 weeks, and having recovered from previous anticancer treatment-related toxicities. We randomly allocated patients (1:1; with blocking [block size of four]; stratified by WHO performance status [0 vs 1-2] and presence or absence of brain metastases) to oral ceritinib 750 mg per day fasted (in 21 day treatment cycles) or chemotherapy (intravenous pemetrexed 500 mg/m2 or docetaxel 75 mg/m2 [investigator choice], every 21 days). Patients who discontinued chemotherapy because of progressive disease could cross over to the ceritinib group. The primary endpoint was progression-free survival, assessed by a masked independent review committee using Response Evaluation Criteria in Solid Tumors 1.1 in the intention-to-treat population, assessed every 6 weeks until month 18 and every 9 weeks thereafter. This trial is registered with ClinicalTrials.gov, number NCT01828112, and is ongoing but no longer recruiting patients. FINDINGS: Between June 28, 2013, and Nov 2, 2015, we randomly allocated 231 patients; 115 (50%) to ceritinib and 116 (50%) to chemotherapy (40 [34%] to pemetrexed, 73 [63%] to docetaxel, and three [3%] discontinued before receiving treatment). Median follow-up was 16·5 months (IQR 11·5-21·4). Ceritinib showed a significant improvement in median progression-free survival compared with chemotherapy (5·4 months [95% CI 4·1-6·9] for ceritinib vs 1·6 months [1·4-2·8] for chemotherapy; hazard ratio 0·49 [0·36-0·67]; p<0·0001). Serious adverse events were reported in 49 (43%) of 115 patients in the ceritinib group and 36 (32%) of 113 in the chemotherapy group. Treatment-related serious adverse events were similar between groups (13 [11%] in the ceritinib group vs 12 [11%] in the chemotherapy group). The most frequent grade 3-4 adverse events in the ceritinib group were increased alanine aminotransferase concentration (24 [21%] of 115 vs two [2%] of 113 in the chemotherapy group), increased γ glutamyltransferase concentration (24 [21%] vs one [1%]), and increased aspartate aminotransferase concentration (16 [14%] vs one [1%] in the chemotherapy group). Six (5%) of 115 patients in the ceritinib group discontinued because of adverse events compared with eight (7%) of 116 in the chemotherapy group. 15 (13%) of 115 patients in the ceritinib group and five (4%) of 113 in the chemotherapy group died during the treatment period (from the day of the first dose of study treatment to 30 days after the final dose). 13 (87%) of the 15 patients who died in the ceritinib group died because of disease progression and two (13%) died because of an adverse event (one [7%] cerebrovascular accident and one [7%] respiratory failure); neither of these deaths were considered by the investigator to be treatment related. The five (4%) deaths in the chemotherapy group were all due to disease progression. INTERPRETATION: These findings show that patients derive significant clinical benefit from a more potent ALK inhibitor after failure of crizotinib, and establish ceritinib as a more efficacious treatment option compared with chemotherapy in this patient population. FUNDING: Novartis Pharmaceuticals Corporation.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Shaw AT, Kim TM, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2017. PMID: 28602779. doi:10.1016/S1470-2045(17)30339-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。